LavoieHealthScience Launches Strategic Communications Solutions for Emerging Health and Science Innovations

LaVoieHealthScience (LHS) announced today the launch of its Emerging Health Convergence Practice focused on providing right-sized, integrated investor and public relations strategy and execution as well as digital communications solutions to companies dedicated to innovating, thriving amid current market uncertainty, and focused on leapfrogging the standard of patient care. The LHS Emerging Convergence Practice focuses on companies in drug development and screening, digital therapeutics, customized treatments and intervention, decision support, prevention, and early disease detection.

Since 2001, LaVoieHealthScience has provided full-service global health and science-based companies with strategic consulting and integrated communications programs in investor relations, public relations, corporate communications, and marketing, including digital solutions. LHS specializes in helping clients build value for their companies and products through understanding the complex business of health and science markets.

“We recognize the need to provide a unique set of services to companies focused on the future of biopharma and medtech that are right sized to fit these companies’ unique communications needs in the current market,” said Donna L. LaVoie, President and CEO of LaVoieHealthScience. “With a strong history in health and science innovation communications services, we are re-imagining our business model to fit the needs of companies without the resources and expertise to obtain share of voice and remain competitive for access to capital, customers, medical audiences, and talent.

LaVoieHealthScience will provide these services under a different services model than the current LHS Health Commercial Practice which works with companies and brands that are preparing for commercial launch, FDA approval, and beyond.” LHS Health Commercial Practice provides elevated services with dedicated teams in investor and media relations, digital, medical audience-based solutions, market shaping, and enhanced investor communications services to support in-house teams in growth mode.

Companies well suited for The LHS Emerging Health Convergence Practice are pre-revenue, venture-backed, or small cap public companies in early clinical development up to Phase 2 or equivalent.

LHS’ Three-Tiered package provides the ability to select the services based on company priorities and budget. The three tiers provide a sliding scale of services for emerging health companies based on where they are in their lifecycle.

IR for Emerging Health Convergence

  • Core IR: Quarterly Reporting, Planning & Execution
  • Investor Relationship Building and Targeted Outreach
    • Right Mix of Investors, Analysts, and Bankers
  • Shaping and Extending Your Investor Message
    • IR LHS Immersion® “Lite”
      • Provides Realignment of Company Story with Investment Thesis to Key
        Investor and Partner Stakeholders
    • Investor Messaging Campaign
      • Press Release Development and Distribution Management
      • Social Media Strategy, including Followers and Reporting
  • Financial and Trade Media Outreach and Distribution
  • Issues Management including Shareholder Activism Readiness and Response
  • JPM Week Planning and Optimization

Corporate Communications and Marketing

  • Website Development Optimized for Easy Updates
  • Logo/Brand Development
  • Tagline Development
  • Scientific/Medical/Technology Illustrations
  • Development of Corporate and Product Marketing Content
    • Fact Sheets
    • Html E-Mails and Newsletters
    • Patient Testimonials
    • Presentation Materials and More

PR for Emerging Health Convergence

  • PR Company/Product Launch Strategy, Plan, and Execution
  • Timeline and Milestone Management
  • Press Release and Social Media Execution
  • Targeted Media Relations Outreach to the Right Media
  • Thought Leadership Programming
  • Corporate Development Strategy and Plan, including Targeted Conferences to Attend with the Right Mix of Investors and Partners
  • Website Optimization including SEO and SMO
  • Strategic Counsel on Capital Formation and Medical Communications Strategy
  • Dissemination of Company Information to:
    • Investors
    • Media
    • Industry Executives
  • Best Practice Regulatory Compliance for Social Media and Promotion

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version